• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Med (Lausanne) . Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China

tetano

Editor, Senior Moderator
Front Med (Lausanne)


. 2022 Jan 10;8:784632.
doi: 10.3389/fmed.2021.784632. eCollection 2021.
Identification of SARS-CoV-2 Variants and Their Clinical Significance in Hefei, China


Xiao-Wen Cheng[SUP] 1 2 [/SUP], Jie Li[SUP] 1 [/SUP], Lu Zhang[SUP] 3 [/SUP], Wen-Jun Hu[SUP] 1 [/SUP], Lu Zong[SUP] 1 [/SUP], Xiang Xu[SUP] 1 [/SUP], Jin-Ping Qiao[SUP] 1 [/SUP], Mei-Juan Zheng[SUP] 1 [/SUP], Xi-Wen Jiang[SUP] 4 5 [/SUP], Zhi-Kun Liang[SUP] 6 [/SUP], Yi-Fan Zhou[SUP] 7 [/SUP], Ning Zhang[SUP] 8 [/SUP], Hua-Qing Zhu[SUP] 2 [/SUP], Yuan-Hong Xu[SUP] 1 [/SUP]



Affiliations

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic represents one of the most exigent threats of our lifetime to global public health and economy. As part of the pandemic, from January 10 to March 10, 2020, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) began to spread in Hefei (Anhui Province, China) with a total of 174 confirmed cases of COVID-19. During this period, we were able to gather critical information on the transmission and evolution of pathogens through genomic surveillance. Particularly, the objective of our study was to track putative variants of SARS-CoV-2 circulating in Hefei for the first time and contribute to the global effort toward elucidating the molecular epidemic profile of the virus. Patients who showed symptoms of COVID-19 were routinely tested for SARS-CoV-2 infections via RT-PCR at the First Affiliated Hospital of Anhui Medical University. Whole-genome sequencing was performed on 97 clinical samples collected from 29 confirmed COVID-19 patients. As a result, we identified a local novel single-nucleotide polymorphism site (10,380) harboring a G → T mutation (Gly → Val) in Hefei. Further phylogenetic network analysis with all the sequences of SARS-CoV-2 deposited in GenBank collected in East and Southeast Asia revealed a local subtype of S-type SARS-CoV-2 (a1) harboring a C → T synonymous mutation (Leu) at position 18,060 of ORF1b, likely representing a local SARS-CoV-2 mutation site that is obviously concentrated in Hefei and the Yangtze River Delta region. Moreover, clinical investigation on the inflammatory cytokine profile of the patients suggested that mutations at positions 18,060 (the shared variable site of subtype a1) and 28,253(harboring a C → T synonymous mutation, Phe) were associated with milder immune responses in the patients.

Keywords: COVID-19; S-type strain; SARS-CoV-2; endemic; genomic surveillance.
 
Back
Top Bottom